Abstract:

Objective To compare the incidence of necrotizing enterocolitis(NEC), bronchopulmonary dysplasia（BPD） and other neonatal disease between preterm infants received LCPUFA-supplemented formula and regular formula. Methods The databases of PubMed,EMBASE,the Cohrane Library, CNKI and Wanfang database were searched from establishment to Augest, 2015, to collect relevant studies investigating the impact of preterm infants given LCPUFA on the incidence of NEC, BPD, sepsis and mortality. Two reviewers independently screened literatures, extracted data,and assessed the risk bias of included studies by modified JADAD scale. The outcomes were expressed as risk ratio(RR) with 95% CI.The meta-analysis was performed using RevMan 5.3 software.A fixed-effect model or a random-effect model would be used acording to the heterogeneity. Results Fifteen RCTs (2 658 infants) were included into this meta-analysis. The JADAD score of 13 RCTs ranged from 5 to 7, whearas 2 RCTs < 5, which indicated the risk of bias of included studies was low. The meta-analysis showed that LCPUFA could not significantly decrease the incidence of NEC, BPD, sepsis or death, the correponding RR(95%CI) was 1.16(0.73-1.83), 0.94（0.79-1.13）, 1.13（0.93-1.37） and 1.15（0.56-2.36）, respectively. Subgroup analysis found that preterm infants with gestational age ≤32 weeks receiving LCPUFA had lower incidence of NEC (RR,0.42,95% CI: 0.19-0.96）. The incidences of BPD and sepsis did not significantly differ in infants reveiving and non-reveiving LCPUFA in the gestational age ≤32 weeks. Conclusion Preterm infants received LCPUFA-supplemented formula could not decrease the incidence of BPD, sepsis and death, however may decrease the incidence of NEC in infants with gestational age less than 32 weeks.